title: Effects of different administration protocols on the plasma concentration of donepezil hydrochloride in dementia patients with stage 5 chronic kidney disease.
abstract: The prevalence of chronic kidney disease (CKD) as well as Alzheimer's disease (AD) increases with age. With the aging of the population in Japan, there is an increasing likelihood that patients with CKD will receive donepezil hydrochloride (DPZ), an antidementia drug, in the near future. Nevertheless, there have been few reports on how to use DPZ in patients with severe CKD. We report on 2 CKD stage 5 patients who received DPZ under different prescriptions. In case 1, 3 mg/day of DPZ was initially administered for 4 months, after which the dose was increased to 5 mg/day. In case 2, 5 mg was administered twice a week. The plasma concentration of DPZ was measured and the effectiveness was assessed using the Mini-Mental Health State Examination and the Hasegawa Dementia Rating Scale. We found that (1) only a slight increase in the plasma concentration of DPZ was observed with a dose of 3 mg daily, (2) there was a significant increase in the plasma concentration with a dose of 5 mg daily, and (3) when 5 mg of DPZ was administered twice a week, the plasma concentration did not differ significantly from healthy controls who had received 5 mg daily. Although cognitive function was improved best when the 5-mg dose was administered daily with no apparent side effects, the plasma concentration came close to reaching a toxic level at this dose. Careful follow-up may be essential when DPZ is used at 5 mg/day or greater in severe CKD patients.
authors.affiliation: Department of Nephrology, Shimane University Hospital, Shimane University Faculty of Medicine, Izumo, Japan ; Department of Functional Pathology, Shimane University Faculty of Medicine, Izumo, Japan.
authors.forename: Chika
authors.initials: C
authors.lastname: Amano
authors.forename: Takafumi
authors.initials: T
authors.lastname: Ito
authors.forename: Masahiro
authors.initials: M
authors.lastname: Egawa
authors.forename: Tomohiro
authors.initials: T
authors.lastname: Oka
authors.forename: Ken
authors.initials: K
authors.lastname: Hanada
authors.forename: Kosuke
authors.initials: K
authors.lastname: Matsui
authors.forename: Toru
authors.initials: T
authors.lastname: Nabika
authors.forename: Kazuaki
authors.initials: K
authors.lastname: Tanabe
keywords: Alzheimer's disease; Chronic kidney disease; Donepezil hydrochloride
references.citation: Chem Rec. 2001;1(1):63-73
references.pmid: 11893059
references.citation: Rinsho Shinkeigaku. 2003 Aug;43(8):482-6
references.pmid: 14658400
references.citation: Neurology. 2009 Sep 22;73(12):920-7
references.pmid: 19657107
references.citation: Science. 1983 Mar 11;219(4589):1184-90
references.pmid: 6338589
references.citation: Arch Intern Med. 1998 May 11;158(9):1021-31
references.pmid: 9588436
references.citation: J Neurosci Res. 1990 Dec;27(4):576-86
references.pmid: 1981917
references.citation: Br J Clin Pharmacol. 2004 Nov;58 Suppl 1:18-24
references.pmid: 15496219
references.citation: Chem Biol Interact. 2008 Sep 25;175(1-3):204-8
references.pmid: 18577377
references.citation: Br J Clin Pharmacol. 1998 Nov;46 Suppl 1:56-60
references.pmid: 9839768
references.citation: Ageing Soc. 1992;12:269-87
references.pmid: 11654434